Table 1 |
|||
|
Correlation betweeen HMG-CoAR expression and clinicopathological parameters. |
|||
| HMG-CoAR intensity |
0 |
1 to 3 |
|
|
|
|||
| n (%) |
111 (25.0) |
333 (75.0) |
p value |
| Age (years) |
|||
| Median |
65 |
64 |
|
| Range |
27 to 89 |
34 to 96 |
0.84 |
| ≤50 |
23 (20.7) |
51 (15.5) |
|
| >50 |
88 (79.3) |
279 (84.5) |
0.20 |
| Tumour size (mm) |
|||
| Median |
20 |
15 |
|
| Range |
1 to 100 |
1 to 100 |
<0.001 |
| ≤20 mm |
57 (51.4) |
217 (65.8) |
|
| >20 mm |
54 (48.6) |
113 (34.2) |
0.007 |
| NHG |
|||
| I |
11 (9.9) |
97 (29.5) |
|
| II |
45 (40.5) |
133 (40.4) |
|
| III |
55 (49.5) |
99 (30.1) |
<0.001 |
| Node status |
|||
| Negative |
67 (65.7) |
179 (61.3) |
|
| Positive |
35 (34.3) |
113 (38.7) |
0.43 |
| Unknown |
9 |
41 |
|
| ER status |
|||
| Negative |
22 (20.0) |
36 (10.9) |
|
| Positive |
88 (80.0) |
294 (89.1) |
0.01 |
| Unknown |
1 |
3 |
|
| PR status |
|||
| Negative |
16 (14.8) |
45 (13.8) |
|
| Positive |
92 (85.2) |
281 (86.2) |
0.79 |
| Unknown |
3 |
7 |
|
| n (%) |
111 (25.0) |
333 (75.0) |
p-value |
| Endocrine therapy (tamoxifen) |
|||
| No |
50 (55) |
147 (59) |
|
| Yes |
41 (45) |
103 (41) |
|
| Unknown |
20 |
83 |
0.53 |
| Chemotherapy |
|||
| No |
81 (89) |
240 (95) |
|
| Yes |
10 (11) |
12 (5) |
|
| Unknown |
20 |
81 |
0.04 |
| HER2 IHC |
|||
| 0 |
77 (73.3) |
155 (48.9) |
|
| 1 |
13 (12.4) |
89 (28.1) |
|
| 2 |
6 (5.7) |
37 (11.7) |
|
| 3 |
9 (8.6) |
36 (11.4) |
<0.001 |
| unknown |
6 |
16 |
|
| HER2 IHC |
|||
| 0 to 2 |
96 (91) |
284 (89) |
|
| 3 |
9 (9) |
36 (11) |
0.44 |
| Unknown |
6 |
16 |
|
| Ki67 |
|||
| 0 to 10% |
29 (27.6) |
122 (39.5) |
|
| 11 to 25% |
35 (33.3) |
107 (34.6) |
|
| >25% |
39 (41.0) |
80 (25.9) |
0.02 |
| Unknown |
8 |
24 |
|
|
|
|||
|
ER = oestrogen receptor; HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; NHG = Nottingham histological grade; PR = progesterone receptor. 10% cut-off used for determination of hormone receptor status. Mann-Whitney test for comparison of medians and chi squared test for X × 2 tables. The categories marked as not done and unknown were not included in the analysis. |
|||
|
Borgquist et al. Breast Cancer Research 2008 10:R79 doi:10.1186/bcr2146 |
|||
